医学
顺铂
听力损失
癌症
化疗
测听
听力学
耳毒性
回顾性队列研究
累积剂量
内科学
作者
Vahid Zand,Mohammad Mandegari,Mohammad Hossein Baradaranfar,Sedighe Vaziribozorg,Ali Shahzeidi
标识
DOI:10.1016/j.amjoto.2023.104127
摘要
In this study we investigated the effect of cisplatin-based chemotherapy on hearing loss in children with cancer. In this retrospective study, 20 children aged 6 to 17 years with cancer who were treated with cisplatin and had normal results on initial audiometry test were included. The demographic, clinical, and medical information of all children was extracted and recorded. The hearing thresholds were determined for the frequency of >8 kHz by an audiometrist two weeks after receiving the last course of cisplatin. Finally, all data was analyzed. In this study, 20 children with cancer were included of who 9 were girls (45 %) and 11 were boys (55 %). The patients' mean age at the time of diagnosis was 6.65 years. Results showed that children who received cisplatin ≥70 mg/m2 (P.value = 0.09) and ≥ 7 courses of cisplatin (P.value = 0.01), and a cumulative dose higher than 400 mg/m2 (P.value = 0.02) had higher chance of hearing loss. According to the results it can be concluded that since higher doses caused higher risk of hearing loss and also since lower doses were effective for treatment of the cancer in children therefore to preventing the hearing loss, lower doses of cisplatin are recommended for cancer treatment in children.
科研通智能强力驱动
Strongly Powered by AbleSci AI